The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
Jersey Mike’s Is Winning the Sandwich War. It Still Needs to Win Over Gen Z.
The chain’s affluent, older base gives it an edge....
Will Hammond starts, leads Texas Tech to victory in opener
Dave WilsonSep 6, 2026, 12:19 AM ETCloseDave Wilson is...
Uber robotaxis hit London’s streets, but with humans still behind the wheel
Robotaxis are on the roads...
No. 16 Michigan catches second-chance Hail Mary
No. 16 Michigan catches second-chance Hail Mary, survives scare...